BRCA1 recognizes a 22 kDa protein. This antibody stains 94 % of ovarian carcinomas with a mutation in exon 11. However, staining was absent in 100 % of tumors with mutations other than exon 11. Cellular Localization: Cytoplasmic.
Purification
None
Immunogen
Peptide corresponding to amino acids 1839-1863 of the c-terminus of BRCA1
BRCA1
Reactivity: Human
WB, IF, IP, FACS, ICC
Host: Mouse
Monoclonal
RAY
unconjugated
Application Notes
Immunohistochemistry on frozen and paraffin sections (ABC method: 1/15 - 1/50, Formalinfixed paraffin embedded tissue sections require high temperature antigen unmasking with10 mM citrate buffer, pH 6.0 prior to immunostaining, Incubation period of 30-60 minutesat room temperature). Use ovarian carcinoma as positive control. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Format
Liquid
Buffer
Tissue culture supernatant with 0.05 % sodium azide as preservative
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing. This product is photosensitive and should be protected from light
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
BRCA1 (breast and ovarian cancer susceptibility protein 1) is a nuclear phosphoprotein that plays a role in maintaining genomic stability and acts as a tumor suppressor. It combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as BASC (for BRCA1 associated genome surveillance complex). BRCA1 associates with RNA polymerase II, and through the C terminal domain, also interacts with histone deacetylase complex. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in the BRCA1 gene are responsible for approximately 40 % of inherited breast cancers and more than 80 % of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants have been described for this gene but only some have had their full length natures identified.Synonyms: Breast cancer type 1 susceptibility protein, RING finger protein 53